斯克里普斯研究所

2023年6月21日

分享这篇文章提供的新闻考夫曼博士加入Oncternal疗法,Inc .普林斯顿大学,新泽西州2023年6月21日,Kyowa从麒麟,Inc .的Kyowa麒麟有限公司有限公司(Kyowa麒麟,谢霆锋:4151),日本的全球专业制药公司,今天宣布贡纳·考夫曼博士已经被命名为研究总监(CRO)。考夫曼博士加入Kyowa麒麟北美(KKNA) Oncternal疗法,Inc .,在那里他担任首席科学官。在他的新角色,考夫曼博士将负责KKNA位于拉霍亚的研究团队,CA,以及开放创新部门,寻求外部合作加速药物发现和新的生物技术的应用。他也担任兼职助理教授斯克里普斯研究所的化学和免疫学和微生物科学的部门。贡纳·f·考夫曼博士命名研究总监Kyowa麒麟”考夫曼博士的领先的药物发现研究和临床前开发将有助于Kyowa麒麟增长我们的未来管道新的药物靶点和治疗候选人有可能解决患者的未满足的需求”,有利于牌坊博士说,全球研究主管Kyowa麒麟。“我们期待着持续增长与学术和技术合作伙伴的合作来满足我们的科学和临床的野心。”An immunologist and chemical biologist, Dr. Kaufmann has experience in discovery and preclinical development of small molecule and biotherapeutics drug product candidates, including monoclonal antibodies, bispecific antibodies, antibody drug conjugates, cellular therapies, and vaccines. He brings expertise in multiple therapeutic areas, including immunology and oncology, as well as preclinical research strategies. He has, throughout his career, taken projects from inception through non-clinical R&D into clinical trials. In his most recent role as CSO at Oncternal Therapeutics, he led all preclinical research activities, oversaw the non-clinical development of a CAR T cell therapy as well as a small molecule prostate cancer program and supported translational research for the clinical programs. Previously, he held numerous roles of increasing responsibility at Sorrento Therapeutics, Inc., most recently serving as Senior Vice President of Immunotherapy, Head of Research and Global Partnerships. There, he built and led a discovery, research, and preclinical development team that successfully supported Sorrento's pipeline of therapeutic and immuno-oncology antibodies, bispecific antibodies, ADCs, oncolytic viruses, and cellular therapies. He also established an immuno-oncology research focus that resulted in a comprehensive portfolio, including out-licensed therapies. Dr. Kaufmann is an active member of the American Association for Cancer Research, the American Association of Immunologists, the Society for ImmunoTherapy of Cancer, and the American Society for Clinical Oncology. He has authored more than 50 peer-reviewed publications. He received his Ph.D. in Biology from The Scripps Research Institute, his Master of Science in Human Biology from the University of Greifswald, Germany, and his Bachelor of Science in Human Biology from The Philipps University, Germany. "I am honored to join Kyowa Kirin and work on innovative projects and partnerships that can contribute to addressing unmet medical needs," said Dr. Kaufmann. "I look forward to working with the incredible KKNA research team and our academic partners, including collaborators at the La Jolla Institute for Immunology, to bring new therapies to patients, their families and caregivers as well as the broader community that surrounds us all." About Kyowa Kirin Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a more than 70-year heritage, we apply cutting-edge science including expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across our four regions – Japan, Asia Pacific, North America, and EMEA/International – we focus on our purpose to make people smile, and are united by our shared values of commitment to life, teamwork/Wa, innovation, and integrity. You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com or https://www.linkedin.com/company/kyowa-kirin-inc.-u.s./ SOURCE Kyowa Kirin